OPKO Health subsidiary ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for ...
Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to PlanOral Minisymposium Presentation Demonstrates That EVOLVE T Cell ...
The activation and regulation of T cells are fundamental to immune homeostasis and effective defence mechanisms. Ubiquitin ligases, such as c-Cbl and Cbl-b, serve as pivotal regulators by targeting ...
Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomasPreclinical ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
KACTUS, a leading recombinant protein manufacturer, has published a technical framework for engineering 2+1 and trispecific T-cell engager (TCE) therapeutics.
Researchers built an immune-aging clock from 1.2 million cells, revealing T cells as key indicators of immune aging. They ...
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results